Molecular status of pituitary carcinoma and atypical adenoma that contributes the effectiveness of temozolomide

被引：0
|
作者：
Akira Matsuno
Mineko Murakami
Katsumi Hoya
Shoko M. Yamada
Shinya Miyamoto
So Yamada
Jae-Hyun Son
Hajime Nishido
Fuyuaki Ide
Hiroshi Nagashima
Mutsumi Sugaya
Toshio Hirohata
Akiko Mizutani
Hiroko Okinaga
Yudo Ishii
Shigeyuki Tahara
Akira Teramoto
R. Yoshiyuki Osamura
机构：
[1] Teikyo University Chiba Medical Center,Department of Neurosurgery
[2] Teikyo University Chiba Medical Center,Department of Rehabilitation
[3] The University of Tokyo,Department of Neurosurgery
[4] Teikyo Heisei University,Department of Neurosurgery
[5] Nippon Medical School,Department of Pathology
[6] International University of Health and Welfare Mita Hospital,undefined
来源：
Medical Molecular Morphology | 2014年 / 47卷
关键词：
Pituitary carcinomas and atypical adenomas; Temozolomide; O; -Methyl-guanine-DNA methyltransferase; Mismatch repair pathway; MSH6;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
There have been several reports of temozolomide (TMZ) treatment of pituitary carcinomas and atypical adenomas. O6-methyl-guanine-DNA methyltransferase is not the sole molecule determining the sensitivity to TMZ in pituitary carcinomas and atypical adenomas. The Japan Society of Hypothalamic and Pituitary Tumors study suggests that MSH6, one of mismatch repair pathway enzyme, fulfills a contributory role to the efficacy of TMZ treatment for pituitary carcinomas and atypical adenomas. The preserved MSH6 function might be essential for the responsiveness to TMZ treatment in pituitary carcinomas and atypical adenomas.
引用
收藏
页码：1 / 7
页数：6
相关论文
共 50 条
  • [21] Atypical, invasive, recurring Crooke cell adenoma of the pituitary
    Fabio Rotondo
    Michael Cusimano
    Bernd W. Scheithauer
    Claire Coire
    Eva Horvath
    Kalman Kovacs
    Hormones, 2012, 11 : 94 - 100
  • [22] Atypical, invasive, recurring Crooke cell adenoma of the pituitary
    Rotondo, Fabio
    Cusimano, Michael
    Scheithauer, Bernd W.
    Coire, Claire
    Horvath, Eva
    Kovacs, Kalman
    HORMONES-INTERNATIONAL JOURNAL OF ENDOCRINOLOGY AND METABOLISM, 2012, 11 (01): : 94 - 100
  • [23] Temozolomide therapy: Focus on patients with pituitary carcinoma
    Curto, Lorenzo
    JOURNAL OF NEUROSCIENCES IN RURAL PRACTICE, 2016, 7 (03) : 335 - 336
  • [24] Non-uniform Response to Temozolomide Therapy in a Pituitary Gonadotroph Adenoma
    Ersen, Ayca
    Syro, Luis V.
    Penagos, Luis C.
    Uribe, Humberto
    Scheithauer, Bernd W.
    Ortiz, Leon D.
    Rotondo, Fabio
    Horvath, Eva
    Kovacs, Kalman
    CANADIAN JOURNAL OF NEUROLOGICAL SCIENCES, 2012, 39 (05) : 683 - 685
  • [25] Temozolomide-induced inhibition of pituitary adenoma cells Laboratory investigation
    Sheehan, Jason
    Rainey, Jessica
    Nguyen, James
    Grimsdale, Ruthie
    Han, Shaojie
    JOURNAL OF NEUROSURGERY, 2011, 114 (02) : 354 - 358
  • [26] Molecular Mechanisms of Pituitary Adenoma Senescence
    Chesnokova, Vera
    Zonis, Svetlana
    Ben-Shlomo, Anat
    Wawrowsky, Kolja
    Melmed, Shlomo
    PITUITARY TODAY II: NEW MOLECULAR, PHYSIOLOGICAL AND CLINICAL ASPECTS, 2010, 38 : 7 - 14
  • [27] Pituitary metastasis from lung carcinoma presenting as a pituitary adenoma
    Lin, David S.
    Griffith, Brent
    Patel, Suresh
    Rock, Jack
    Marin, Horia
    APPLIED RADIOLOGY, 2018, 47 (07) : 34 - 36
  • [28] SIRT1 Contributes as an Invasiveness Marker in Pituitary Adenoma
    Vaiciulis, Domantas
    Vilkeviciute, Alvita
    Gedvilaite, Greta
    Glebauskiene, Brigita
    Kriauciuniene, Loresa
    Liutkeviciene, Rasa
    BRAIN SCIENCES, 2021, 11 (12)
  • [29] Pituitary Adenoma Nitroproteomics: Current Status and Perspectives
    Zhan, Xianquan
    Wang, Xiaowei
    Desiderio, Dominic M.
    OXIDATIVE MEDICINE AND CELLULAR LONGEVITY, 2013, 2013
  • [30] Implications of MGMT methylation status in pituitary adenoma
    Arya, Sneha
    Majaid, M. A.
    Shwetha, S. D.
    Sravani, K.
    Arivazhagan, A.
    Sampath, S.
    Santosh, V.
    PATHOLOGY RESEARCH AND PRACTICE, 2014, 210 (07) : 407 - 411
12345